Vonvendi® [von Willebrand factor (recombinant)] – Expanded indication

- On April 17, 2018, Shire announced the FDA approval of Vonvendi [von Willebrand factor (recombinant)] for perioperative management of bleeding in adults (age 18 and older) diagnosed with von Willebrand disease (VWD).
    - Previously, Vonvendi was indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with VWD.
- According to the National Hemophilia Foundation, VWD affects up to 1% of the U.S. population, and is the most common bleeding disorder.
- The efficacy of Vonvendi in perioperative management of bleeding was assessed in an open-label trial of 15 patients with VWD who underwent surgery. Patients were allowed the use of Advate® [antihemophilic factor (recombinant)] in addition to Vonvendi. Hemostatic efficacy was measured on a 4-point efficacy scale (excellent, good, moderate, and none) where a rating of excellent or good was required to declare the outcome a success.
    - Overall hemostatic efficacy was 100% (90% CI: 81.9%, 100%).
- The most common adverse reactions (≥ 2%) with Vonvendi use were generalized pruritus, nausea, and dizziness.
    - One subject treated with Vonvendi in the perioperative setting developed deep vein thrombosis after undergoing total hip replacement surgery.
- For perioperative management of bleeding, dosage and frequency of Vonvendi must be individualized according to clinical judgement, weight, type and severity of the bleeding episodes/surgical intervention, and clinical and laboratory measures.
- Refer to the Vonvendi prescribing information for full dosing information for both indications.